SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Ardent Health Partners, LLC (ARDT) trades at a trailing P/E of 9.6, forward P/E of 8.3. Trailing earnings yield is 10.39%, forward earnings yield 12.12%. PEG 0.43 (Peter Lynch undervalued ≤1.0). Graham Number is $16.12.
Criteria proven by this page:
- VALUE (96/100, Pass) — P/E is below market average (9.6); PEG ≤ 1.0 — Peter Lynch undervalued (0.43); analyst target implies upside (+50.1%); earnings yield beats bond yields (10.39%).
- Forward P/E 8.3 (down from trailing 9.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.43 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 10.39% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 12.12% as earnings recover.
- Analyst consensus target $14.14 (+50.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 75/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
96/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARDT
Valuation Multiples
P/E (TTM)9.6
Forward P/E8.3
PEG Ratio0.43
Forward PEG0.43
P/B Ratio0.78
P/S Ratio0.21
EV/EBITDA5.7
Per Share Data
EPS (TTM)$0.96
Forward EPS (Est.)$1.14
Book Value / Share$11.97
Revenue / Share$44.93
FCF / Share$1.81
Yields & Fair Value
Earnings Yield10.39%
Forward Earnings Yield12.12%
Dividend Yield0.00%
Graham Number$16.12
SharesGrow IV$47.37 (+402.9%)
Analyst Target$14.14 (+50.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2015 |
-48.8 |
0.00 |
0.00 |
1.12 |
24.67% |
| 2016 |
155.0 |
-1.19 |
8.49 |
1.08 |
- |
| 2017 |
-63.5 |
0.18 |
5.99 |
0.75 |
- |
| 2018 |
-15.8 |
-0.05 |
6.83 |
0.54 |
- |
| 2021 |
14.9 |
0.00 |
0.00 |
0.47 |
2.70% |
| 2022 |
12.2 |
0.55 |
3.60 |
0.45 |
7.60% |
| 2023 |
45.7 |
-0.62 |
3.43 |
0.43 |
- |
| 2024 |
10.8 |
0.03 |
2.00 |
0.38 |
- |
| 2025 |
9.2 |
-0.23 |
0.74 |
0.20 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.33 |
$2.03B |
$-46.36M |
-2.3% |
| 2016 |
$0.10 |
$2.11B |
$14.6M |
0.7% |
| 2017 |
$-0.25 |
$3B |
$-35.65M |
-1.2% |
| 2018 |
$-1.01 |
$4.16B |
$-143.02M |
-3.4% |
| 2021 |
$1.09 |
$4.87B |
$154.26M |
3.2% |
| 2022 |
$1.32 |
$5.13B |
$188.91M |
3.7% |
| 2023 |
$0.35 |
$5.41B |
$50.29M |
0.9% |
| 2024 |
$1.58 |
$5.97B |
$210.34M |
3.5% |
| 2025 |
$0.96 |
$6.32B |
$135.81M |
2.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.14 |
$1.03 – $1.37 |
$6.57B |
$6.55B – $6.61B |
7 |
| 2027 |
$1.26 |
$1.02 – $1.48 |
$6.85B |
$6.79B – $6.9B |
6 |
| 2028 |
$1.34 |
$1.07 – $1.57 |
$7.2B |
$7.2B – $7.2B |
6 |
